Eyerising International

Eyerising International is an Australian MedTech company dedicated to developing innovative therapies for eye health, specifically targeting the progression of myopia in children. Their main product, the Eyerising Myopia Management Device, utilizes proprietary Repeated Low-Level Red-Light (RLRL) therapy. This device stimulates blood flow in the back of the eye, helping to thicken the choroid layer and manage sclera hypoxia, which are key factors in controlling myopia progression. Designed for home use, the device is suitable for children aged 3 to 16 years. Treatment involves looking into the device for just 3 minutes twice daily, five days a week. Clinical trials have shown that this therapy can reduce myopia progression by up to 87.7%. Eyerising International is led by a team of esteemed ophthalmology experts and aims to provide an effective, less invasive treatment option compared to traditional methods. Their target customers include children with myopia, their families, and eye care practitioners. The device is clinically approved and meets Australian safety standards for laser products.

• Employees 9